These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21697252)

  • 1. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
    Modan-Moses D; Koren I; Mazor-Aronovitch K; Pinhas-Hamiel O; Landau H
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2312-7. PubMed ID: 21697252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
    Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
    Giri D; Price V; Yung Z; Didi M; Senniappan S
    J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):347-50. PubMed ID: 27087264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.
    Shah P; Rahman SA; McElroy S; Gilbert C; Morgan K; Hinchey L; Senniappan S; Levy H; Amin R; Hussain K
    Horm Res Paediatr; 2015; 84(5):355-60. PubMed ID: 26375451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
    van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
    Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
    Novokreshhennyx EE; Gubaeva DN; Melikyan MA
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):70-78. PubMed ID: 33369374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
    Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
    Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
    Díez JJ; Iglesias P
    J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of a Long-Acting Somatostatin Analogue (Lanreotide) in Three Children with Focal Forms of Congenital Hyperinsulinaemic Hypoglycaemia.
    Dastamani A; Güemes M; Pitfield C; Morgan K; Rajab M; Rottenburger C; Bomanji J; De Coppi P; Dattani M; Shah P
    Horm Res Paediatr; 2019; 91(1):56-61. PubMed ID: 30114684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
    Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
    J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.